未登录

Z

Zeyu Yu

department of interventional radiology

H指数:3

被引数:29

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Transarterial chemoembolization for advanced hepatocellular carcinoma after failure of first-line systemic treatment: a single-center case series

经动脉化疗栓塞术治疗一线系统性治疗失败后的晚期肝细胞癌：一项单中心病例系列研究

Discover Oncology

IF2.9

2025-08-080

OAAI

Hepatic arterial infusion chemotherapy (HAIC) plus Lenvatinib and PD-1 inhibitors versus systemic chemotherapy for unresectable intrahepatic cholangiocarcinoma

肝动脉灌注化疗（HAIC）联合仑伐替尼和PD-1抑制剂与系统性化疗治疗不可切除的肝内胆管癌

DISCOVER ONCOLOGY

IF2.9

2025-05-160

OA

Comparison of liver injury and inflammatory response following conventional and drug-eluting bead transcatheter chemoembolization in hepatocellular carcinoma

比较常规和载药微球经导管化疗栓塞术在肝细胞癌中引起的肝损伤和炎症反应

DISCOVER ONCOLOGY

IF2.9

2025-04-100

OA

Lenvatinib plus immunotherapy versus lenvatinib monotherapy in lenvatinib-insensitive patients with unresectable hepatocellular carcinoma: a retrospective study

Lenvatinib联合免疫疗法与lenvatinib单药治疗对lenvatinib不敏感的不可切除肝细胞癌患者的回顾性研究

INVESTIGATIONAL NEW DRUGS

IF2.7

2025-01-070

OAAI

A Transcriptomic Biomarker for Predicting the Response to TACE Correlates with the Tumor Microenvironment and Radiomics Features in Carcinoma

预测TACE反应的转录组生物标志物与肿瘤微环境和肿瘤放射组学特征相关

JOURNAL OF HEPATOCELLULAR CARCINOMA

IF3.4

2024-11-010

OAAI

Immune-Targeted Therapy with or without Transarterial Chemoembolization (TACE) for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis (PVTT): A Multicenter Retrospective Study

IF3.9

2024-09-190

OAAI

Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors versus lenvatinib and PD-1 inhibitors for HCC refractory to TACE

肝动脉灌注化疗联合乐伐替尼和PD-1抑制剂与乐伐替尼和PD-1抑制剂治疗TACE难治性肝癌

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

IF3.4

2024-01-199

PRE